Cipla is reportedly planning to enter the branded formulation market in China in coming quarters either by acquiring a company or collaborating with a local partner. The company is planning to focus on respiratory therapeutics in the country.
Cipla’s proposed entry into China’s branded respiratory segment is in line with its pursuit to build a global respiratory franchise. The segment alone contributed about one-fifth to Cipla’s sales of Rs 14,630 crore in FY17.
Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.
